A computer-implemented method for predicting coronary artery disease by scoring a sample obtained from a subject, comprising: obtaining a dataset associated with the sample, wherein the dataset comprises a quantitative expression level value for each marker in at least one term selected from the group consisting of term 1, term 2, term 3, term 4, term 5, term 6, and term 7; wherein term 1 comprises marker 1, marker 2, and marker 3, wherein marker 1 comprises GenBank accession number AF161365, wherein marker 2 comprises HNRPF or ACBD5, and wherein marker 3 comprises TFCP2 or DDX18; wherein term 2 comprises marker 4, marker 5, and marker 6, wherein marker 4 comprises AF289562 or CD248, wherein marker 5 comprises HNRPF or ACBD5, and wherein marker 6 comprises TFCP2 or DDX18; wherein term 3 comprises marker 7, marker 8, marker 9, and marker 10 wherein marker 7 comprises CD79B or CD19, wherein marker 8 comprises SPIB or BLK, wherein marker 9 comprises CD3D or LCK, and wherein marker 10 comprises TMC8 or CCT2; wherein term 4 comprises marker 11, marker 12, marker 13, and marker 14, wherein marker 11 comprises S100A12 or MMP9, wherein marker 12 comprises CLEC4E or ALOX5AP, wherein marker 13 comprises S100A8 or NAMPT, and wherein marker 14 comprises RPL28 or SSRP1; wherein term 5 comprises marker 15, marker 16, marker 17, marker 18, and marker 19, wherein marker 15 comprises S100A12 or MMP9, wherein marker 16 comprises CLEC4E or ALOX5AP, wherein marker 17 comprises S100A8 or NAMPT, wherein marker 18 comprises AQP9 or GLT1D1, and wherein marker 19 comprises NCF4 or NCF2; wherein term 6 comprises marker 20, marker 21, marker 22, marker 23, marker 24, marker 25, and marker 26, wherein marker 20 comprises CASP5 or H3F3B, wherein marker 21 comprises IL18RAP or TXN, wherein marker 22 comprises TNFAIP6 or PLAUR, wherein marker 23 comprises IL8RB or BCL2A1, wherein marker 24 comprises TNFRSF10C or PTAFR, wherein marker 25 comprises KCNE3 or LAMP2, and wherein marker 26 comprises TLR4 or TYROBP; and wherein term 7 comprises marker 27, marker 28, marker 29, and marker 30, wherein marker 27 comprises SLAMF7 or CX3CR1, wherein marker 28 comprises KLRC4 or CD8A, wherein marker 29 comprises CD3D or LCK, and wherein marker 30 comprises TMC8 or CCT2; and determining, by a computer processor, a score from the dataset using an interpretation function, wherein a higher score relative to a control having less than 50% stenosis in all major vessels indicates that the subject has a higher likelihood of CAD. obtaining a dataset associated with the sample, wherein the dataset comprises a quantitative expression level value for each marker in at least one term selected from the group consisting of term 1, term 2, term 3, term 4, term 5, term 6, and term 7; wherein term 1 comprises marker 1, marker 2, and marker 3, wherein marker 1 comprises GenBank accession number AF161365, wherein marker 2 comprises HNRPF or ACBD5, and wherein marker 3 comprises TFCP2 or DDX18; wherein term 2 comprises marker 4, marker 5, and marker 6, wherein marker 4 comprises AF289562 or CD248, wherein marker 5 comprises HNRPF or ACBD5, and wherein marker 6 comprises TFCP2 or DDX18; wherein term 3 comprises marker 7, marker 8, marker 9, and marker 10 wherein marker 7 comprises CD79B or CD19, wherein marker 8 comprises SPIB or BLK, wherein marker 9 comprises CD3D or LCK, and wherein marker 10 comprises TMC8 or CCT2; wherein term 4 comprises marker 11, marker 12, marker 13, and marker 14, wherein marker 11 comprises S100A12 or MMP9, wherein marker 12 comprises CLEC4E or ALOX5AP, wherein marker 13 comprises S100A8 or NAMPT, and wherein marker 14 comprises RPL28 or SSRP1; wherein term 5 comprises marker 15, marker 16, marker 17, marker 18, and marker 19, wherein marker 15 comprises S100A12 or MMP9, wherein marker 16 comprises CLEC4E or ALOX5AP, wherein marker 17 comprises S100A8 or NAMPT, wherein marker 18 comprises AQP9 or GLT1D1, and wherein marker 19 comprises NCF4 or NCF2; wherein term 6 comprises marker 20, marker 21, marker 22, marker 23, marker 24, marker 25, and marker 26, wherein marker 20 comprises CASP5 or H3F3B, wherein marker 21 comprises IL18RAP or TXN, wherein marker 22 comprises TNFAIP6 or PLAUR, wherein marker 23 comprises IL8RB or BCL2A1, wherein marker 24 comprises TNFRSF10C or PTAFR, wherein marker 25 comprises KCNE3 or LAMP2, and wherein marker 26 comprises TLR4 or TYROBP; and wherein term 7 comprises marker 27, marker 28, marker 29, and marker 30, wherein marker 27 comprises SLAMF7 or CX3CR1, wherein marker 28 comprises KLRC4 or CD8A, wherein marker 29 comprises CD3D or LCK, and wherein marker 30 comprises TMC8 or CCT2; and determining, by a computer processor, a score from the dataset using an interpretation function, wherein a higher score relative to a control having less than 50% stenosis in all major vessels indicates that the subject has a higher likelihood of CAD.